DataMeds Welcomes FDA's Proposed Interim Policy on Peptide Compounding

Key Facts

1The U.S. FDA issued a new proposed interim access policy for compounding using certain peptides.

2DataMeds AI announced a roadmap for its Corexa Health division to serve the emerging compounded peptide market.

The U.S. FDA issued a new proposed interim access policy for compounding using certain peptides. ACCESS Newswire reported that DataMeds AI announced a roadmap for its Corexa Health division to serve the emerging compounded peptide market in response to the policy shift.

The proposal follows a recommendation by the FDA's Pharmacy Compounding Advisory Committee to loosen restrictions on specific peptides. MEDS closed at $2.85 on October 15, 2026, after reaching a day high of $2.88 and a low of $2.65.